Presenters
Course Details
Hypertension is one of the most common comorbidities of patients with chronic obstructive pulmonary disease (COPD). In this episode of Hypertension Weekly Practice Webisodes of the Philippine Society of Hypertension, Dr. Patrick Gerald Moral (University of Sto. Tomas) explained the multiple correlations and interactions between COPD and hypertension and outlined the management principles of hypertension management in patients with both conditions. Dr. Helen Ong-Garcia (St. Luke’s Medical Center) then explained the role of angiotensin receptor blockers in the control of hypertension in patients with COPD, and the potential role of telmisartan in maximizing cardiovascular outcomes in high-risk patients.
About the speakers
Dr. Patrick Gerald Moral is an Associate Professor at the UST Faculty of Medicine and Surgery and a Fellow and Past President of the Philippine College of Chest Physicians (PCCP) and the Philippine Society of Sleep Medicine.
Dr. Helen Ong-Garcia is the Vice President for Quality and Patient Safety of St. Luke’s Medical Center and the Section Head of the Stress Laboratory of St. Luke’s Medical Center Global City. She is also the Head of Cardiac Rehabilitation at Chinese General Hospital.
Estimated time of Completion: 1 hr. 6 mins. 23 sec.
CPD Points: 0.75 Point
PRC Program No: PROG-2022-41988
PSH Webisode Series: Treatment in Hypertension in Patients with COPD Course Outline
Patrick Moral, MD, FPCCP
- COPD and Hypertension
- Chronic Lung Diseases Worldwide
- Prevalence of Chronic Obstructive Lung Disease
- How many of your patients with COPD have hypertension?/How many of your hypertensive patients have COPD?
- Prevalence of Hypertension vs. COPD
- COPD mortality
- Causes of COPD
- Alveolar septum
- COPD with pulmonary hypertension
- COPD management
- COPD severity and co-morbidities
- Sleep, SDB and COPD
- Sleep and aging
- NREM and Breathing
- PREM and Breathing
- Characteristics of OSA patients
- REM Sleep Imposes a Vascular Load in COPD Patients Independent of Sleep Apnea
- OSA Pathophysiology
- COPD and OSA
- Symptoms and clinical presentation of OVS compared to OSA
- Prevalence of hypertension with increasing OSA severity
- COPD-OSA survival
- COPD-OSA Overlap
- Excess costs in COPD treatment
- Key points in treating hypertension in patients with COPD
- Thiazides: Disease related considerations
- Thiazides: Drug related considerations
- Loop diuretics: Disease related considerations
- Loop diuretics: Drug related considerations
- ACE inhibitors: Disease related considerations
- ACE inhibitors: Drug related considerations
- ARBs: Disease related considerations
- ARBs: Drug related considerations
- CCBs: Disease related considerations
- CCBs: Drug related considerations
- Considerations for Beta-Blocker Use in Patients with COPD
- Beta-blockers: Disease related considerations
- Beta-blockers: Drug related considerations
- Adherence for Patients
- Effect of illness perception and cultural beliefs on medication adherence
- COPD patient charter
Helen Ong-Garcia, MD
- ARBs in the treatment of hypertension in COPD patients
- COPD and Hypertension
- Interaction of CVD and COPD
- Treatment of hypertension in COPD
- ARBs and COPD mortality (Ho et al 2014), (Ekstrom et al 2013)
- Why ARBs for hypertensive patients with COPD?
- Telmisartan as treatment of hypertension in high CV-risk patients
- Pharmacological Profile of Telmisartan
- The Trough/Peak Ratio
- Comparative Pharmacokinetic Profile
- Telmisartan’s Long Duration of Effect
- ONTARGET
- Telmisartan is As Effective as Ramipril in Preventing CV Events at Increase CV Risk
- Summary
PC-PH-103173 / September 2023